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Abstract
AIM
To investigate the adhesion and anti-inflammatory effects 
of Lactobacillus rhamnosus  GG (LGG) in the colonic mu-
cosa of healthy and ulcerative colitis (UC) patients, both in 
vivo and ex vivo in an organ culture model.
METHODS
For the ex vivo  experiment, a total of 98 patients (68 UC 
patients and 30 normal subjects) were included. Endo-
scopic biopsies were collected and incubated with and 
without LGG or LGG-conditioned media to evaluate the 
mucosal adhesion and anti-inflammatory effects [reduction 
of tumor necrosis factor alpha (TNFα) and interleukin 
(IL)-17 expression] of the bacteria, and extraction of 
DNA and RNA for quantification by real-time (RT)-PCR 
occurred after the incubation. A dose-response study was 
performed by incubating biopsies at “regular”, double and 
5 times higher doses of LGG. For the in vivo experiment, 
a total of 42 patients (20 UC patients and 22 normal 
controls) were included. Biopsies were taken from the 
colons of normal subjects who consumed a commercial 
formulation of LGG for 7 d prior to the colonoscopy, 
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and the adhesion of the bacteria to the colonic mucosa 
was evaluated by RT-PCR and compared with that of 
control biopsies from patients who did not consume the 
formulation. LGG adhesion and TNFα and IL-17 expression 
were compared between UC patients who consumed a 
regular or double dose of LGG supplementation prior to 
colonoscopy.
RESULTS
In the ex vivo  experiment, LGG showed consistent 
adhesion to the distal and proximal colon in normal 
subjects and UC patients, with a trend towards higher 
concentrations in the distal colon, and in UC patients, ad-
hesion was similar in biopsies with active and quiescent 
inflammation. In addition, bioptic samples from UC 
patients incubated with LGG conditioned media (CM) 
showed reduced expression of TNFα and IL-17 compared 
with the corresponding expression in controls (P < 0.05). 
Incubation with a double dose of LGG increased mucosal 
adhesion and the anti-inflammatory effects (P < 0.05). 
In the in vivo  experiment, LGG was detectable only in the 
colon of patients who consumed the LGG formulation, and 
bowel cleansing did not affect LGG adhesion. UC patients 
who consumed the double LGG dose had increased muco-
sal concentrations of the bacteria and reduced TNFα and 
IL-17 expression compared with patients who consumed 
the regular dose (48% and 40% reduction, respectively, P 
< 0.05).
CONCLUSION
In an ex vivo organ culture model, LGG showed consistent 
adhesion and anti-inflammatory effects. Colonization by 
LGG after consumption for a week was demonstrated 
in vivo in the human colon. Increasing the administered 
dose increased the adhesion and effectiveness of the 
bacteria. For the first time, we demonstrated that LGG 
effectively adheres to the colonic mucosa and exerts anti-
inflammatory effects, both ex vivo and in vivo.
Key words: Lactobacillus rhamnosus  GG; Ulcerative 
colitis; Probiotic; Adhesion; Cytokines
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Since probiotic utilization is often driven by un-
proven health claims, we intended to explore the feasibility 
and effectiveness of a safe and well-characterized pro-
biotic bacterial species, the Lactobacillus rhamnosus 
GG (LGG), in ulcerative colitis (UC) patients, through a 
preclinical proof-of-concept study. We demonstrated for 
the first time effective mucosal colonization and the anti-
inflammatory effect of LGG, both ex vivo and in vivo , by 
quantifying bacterial DNA and cytokine RNA expression 
directly at the mucosal site using genomic techniques. 
Further translational and clinical studies would confirm the 
utility and optimize the therapeutic administration of LGG 
in UC patients.
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INTRODUCTION
Recent research has shown a relevant role for the 
intestinal microbiota in health maintenance and dis­
ease occurrences, and consequently, microbiota ma­
nipulation by probiotic bacteria has been proposed as a 
therapeutic option in different pathologic conditions[1]. 
Nonetheless, the clinical utilization of probiotic bacteria 
still lacks robust, specific scientific evidence, and it is 
instead driven by commercial suggestions and generic, 
unproven health benefits. In particular, some probiotic 
strains have shown anti­inflammatory effects in vitro 
and in experimental models, suggesting a potential cli­
nical utilization in intestinal inflammatory pathologies 
such as inflammatory bowel disease (IBD). In fact, 
IBD is a chronic condition of unknown aetiology and im­
munologic pathogenesis, characterized by persistent, 
deregulated inflammation in the intestine that clinically 
manifests with cyclic flares and remission states[2]. 
Therapeutic options include aminosalicylates, corticoste­
roids, and immunosuppressant and biologic drugs, 
but a consistent set of patients still do not respond ade­
quately, so the optimization of conventional therapy 
and the development of novel drugs are desirable. In 
this scenario, the proposal and scientific investigation 
of probiotics as a therapeutic option in IBD patients 
may represent a relevant improvement in clinical man­
agement. Of the two main categories of that disease, 
namely, Crohn’s disease and ulcerative colitis (UC), the lat­
ter appears more sensitive to a possible clinical utilization 
of probiotic bacteria, and indeed, a number of clinical 
studies have explored that possibility[3]. Nonetheless, the 
positive results of those bacteria in experimental and in 
vitro systems still need to be translated with the same 
efficacy to the clinical setting. A possible explanation 
for the lack of consistent clinical data on the therapeutic 
efficacy of probiotic bacteria in UC patients may be ac­
counted for by two major limitations in available studies. 
First, clinical studies showed a large variability in terms 
of the probiotic species used, dosages, duration of 
therapy and end points analysed[4,5]. Second, in those 
studies, the same baseline clinical condition shows con­
sistent heterogeneity in terms of extension, severity 
and duration of disease, with evident implications for 
the evaluation of probiotic efficacy in specific situations. 
In this regard, a reduction in heterogeneity through 
methods and protocols standardization may be the 
key to the improvement of the results of probiotic 
therapeutic application in UC. In particular, preclinical 
studies investigating specific properties of probiotics in 
the human colonic mucosa, such as mucosal adhesion 
and cytokine modulation, are scarce. Although the 
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mechanism of action of probiotic bacteria is still not 
completely clear and likely involves multiple pathways, 
the capacity of the bacteria to adhere to the target site 
(i.e., the colonic mucosa) and to promote a shift in the 
cytokine balance towards a regulatory pattern appears 
to be of particular relevance[6]. In fact, in UC patients, 
a relative increase in proinflammatory cytokines, such 
as tumor necrosis factor alpha (TNFα) and interleukin 
(IL)­17, with a concomitant reduction in regulatory 
mediators [i.e., transforming growth factor beta (TGFβ) 
and IL­10] has been described[7,8]. The demonstration 
of adhesion and mucosal anti­inflammatory effects by 
a well­characterized probiotic bacterium in the human 
colonic mucosa may be of great impact for the proposal 
of selected bacteria for the clinical treatment of UC. 
Then, to appropriately address and implement probiotic 
utilization in specific diseases, it appears to be of great 
importance to perform a methodological evaluation of a 
specific bacterial species as a real “biotherapeutic” agent, 
evaluating the characteristics of the bacterial species 
and its specific mechanisms of action in the same way 
as drugs, as this would have particular relevance for 
clinical and preclinical studies that include appropriate 
experimental models, dose and therapeutic scheme 
evaluations, and potential specific effects for the single 
pathologic condition. In addition, since probiotics are 
generally considered safe, but some important adverse 
events may still occur, especially in critically ill patients[9], 
safety evaluations should be included as well.
Lactobacillus rhamnosus GG ATCC 53103 (LGG) re­
presents an ideal probiotic for such a study, since it is the 
bacterium most intensely investigated in the literature, 
with documented anti­inflammatory effects in vitro and 
solid safety data[10­13]. Preliminary clinical studies support 
the possible utilization of LGG preparations for main­
taining remission in UC patients[14]. 
The aim of the present study was to explore the 
feasibility and potential efficacy of the clinical utilization 
of LGG in UC patients, testing the adhesion and mucosal 
anti­inflammatory effects of probiotic bacteria in an ex 
vivo experimental model and in a proof­of­concept in 
vivo study.
MATERIALS AND METHODS
Ex vivo experiment
Patients: We included patients with UC and normal 
controls who underwent a rectosigmoidoscopy or com­
plete colonoscopy for different clinical indications, and 
all participants gave informed consent for the study. The 
study was approved by the S. Andrea Hospital ethics 
committee. Patients and controls did not consume 
antibiotics, probiotics or laxatives in the month before 
the endoscopy. Standard cleansing preparation by the 
participants has been assumed. For UC patients, we 
included only patients in remission or with mild to mo­
derate disease (clinical Mayo score < 7) who were not 
treated with immunosuppressants, biologic drugs or 
corticosteroids during the course of the study. A total of 
68 UC patients and 30 normal subjects were included in 
the study for the ex vivo experiment.
Bioptic samples: Biopsies from UC patients and normal 
controls were collected during colonoscopy. With an ex 
vivo experimental model, we intended to test mucosal 
adhesion and cytokine modulation by LGG (ATCC 53103) 
in normal and inflamed colonic mucosa. To test adhesion, 
bioptic samples were collected from the proximal (cae­
cum) and distal (rectum) colon of normal subjects (n 
= 20 samples per group) and UC patients (n = 15 per 
group). Moreover, bioptic samples from the rectum of 
UC patients with quiescent (defined as Mayo endoscopic 
score 0­1) and active (Mayo endoscopic score = 2) 
inflammation were collected (n = 15 per group). Bioptic 
specimens were placed in Roswell Park Memorial Institute 
medium (RPMI 1640, Sigma­Aldrich, St Louis, MO, 
United States), a standard medium commonly used for 
cell culture composed of a bicarbonate buffering system 
and different amounts of amino acids and vitamins, with 
the addition of LGG at a concentration of 6 × 106 CFU 
in each sample. After incubation at 37 ℃ for 2 h, the 
bioptic samples were collected and washed two times in 
fresh PBS and finally put in RNAlater solution (Qiagen, 
Valencia, CA, United States) for future utilization. For 
cytokine evaluation, biopsies from the caecum (n = 
15) and rectum (n = 20) of UC patients and normal 
controls (n = 10) were collected and incubated in RPMI 
1640 medium for 6 hours at 37 ℃ with or without LGG­
conditioned media (CM) prepared according to a protocol 
modified from Petrof et al[15] and used at a 1:10 ratio 
in each sample. After incubation, samples were stored 
in RNAlater solution until they were processed. The 
incubation time for the organ cultures was optimized 
by evaluating the expression and degradation of DNA/
RNA indirectly by the quantification of the expression 
of the housekeeping genes (β­actin and GADPH) after 
incubation at different time points (2, 6, 12, and 24 h).
Additionally, a dose­finding study was performed, and 
a total of 18 UC patients with quiescent inflammation 
(Mayo endoscopic score 0­1) were included. For adhesion 
evaluation, bioptic samples from the rectum were incu­
bated with a regular dose (6 × 106 CFU), a double dose 
(1.2 × 107 CFU) or a 5­fold higher dose (3 × 107 CFU) 
of LGG, as previously described (n = 8 per group). For 
cytokine expression quantification, bioptic samples from 
the rectum were incubated with a regular dose (1:10), a 
double dose (2:10) or a 5­fold higher dose (5:10) of LGG 
CM (n = 10 per group), as previously described. After 
incubation, samples were stored in RNAlater solution for 
processing.
For adhesion evaluation, total DNA was extracted 
and mucosa­adherent LGG were quantified by real­
time (RT)­PCR with specific primers already described 
in the literature[16]. A standard curve was obtained by 
10 × serial dilutions of a previously amplified sample. 
For the evaluation of cytokine expression, total RNA 
was extracted, and TNFα and IL­17 concentrations were 
quantified by real time (RT)­PCR with specific primers 
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Laboratories, Inc., Hercules, CA, United States) and 4 
μL target DNA, with an iCyclerQ detection system (Bio­
Rad Laboratories, Inc., Hercules, CA, United States). For 
every set of primers, the original cycle conditions were 
maintained. A total of 35 cycles per reaction were per­
formed. Data were expressed as a ratio relative to the 
lowest value detected after normalization to the internal 
control beta­actin. After reactions, PCR products were 
run on a 2% agarose gel with ethidium­bromide staining 
for visualization.
Statistical analysis
Data are expressed as the mean ± standard error (SE). 
t tests for paired data and for independent samples 
were used for statistical comparisons. A P value < 0.05 
was considered significant. MedCalc statistical software 
version 12.5 (MedCalc Software, Ostend, Belgium) was 
used for analysis.
RESULTS
Ex vivo experiment
After incubation, LGG effectively adhered to the colonic 
mucosa in the ex vivo organ culture experimental model. 
In specimens from the normal colon, LGG showed 
consistent adhesion to the mucosa of bioptic samples 
from both the distal and proximal colon (20.4 ± 6.5 vs 
9.5 ± 2.3, P = NS) (Figure 1A). Considering relative 
segmental adhesion, there was a trend for higher con­
centrations of LGG adhered to the distal vs proximal 
colon (2­fold relative increment), but the difference was 
not statistically significant. Similarly, in UC patients, LGG 
showed remarkable adhesion in bioptic samples from the 
proximal and distal colon, with a trend towards higher 
concentrations in the rectum (10.9 ± 2.9 vs 6.5 ± 2.5, 
P = NS) (Figure 1B). Moreover, LGG showed similar 
adhesion in mucosal biopsies with endoscopically active 
and quiescent inflammation, indicating that inflammatory 
activity does not impair the local adhesion of the bacteria 
(6.2 ± 2.8 vs 6.6 ± 1.2, P = NS) (Figure 2).
Considering cytokine modulation, incubation of 
mucosal samples from UC patients with LGG induced 
a reduction in proinflammatory cytokines. In fact, the 
mucosal expression of TNFα was significantly reduced 
in bioptic samples from both the proximal and distal 
colon incubated with LGG CM compared with biopsies 
incubated without LGG CM (proximal: 6.8 ± 1.0 vs 
16.3 ± 4.7, distal: 3.0 ± 0.4 vs 5.6 ± 1.2, P < 0.05 for 
paired samples for both) (Figure 3A). Similarly, IL­17 
expression was reduced in LGG CM­incubated distal 
colon bioptic samples (proximal: 2.4 ± 0.6 vs 2.6 ± 0.7, P 
= NS; distal: 3.0 ± 0.3 vs 3.7 ± 0.3, P < 0.05 for paired 
samples) (Figure 3B). Similar results were observed 
when LGG CM was incubated with normal mucosa 
specimens (Figure 3C).
In the dose­response experiment, incubation with 
a double dose of LGG increased the bacterial DNA con­
tent of the bioptic specimens compared to that of the 
and expressed in relation to the expression of the internal 
β­actin control. Primers for TNFα, β­actin, and IL­17 were 
ordered from Qiagen (Valencia, CA, United States).
In vivo experiment
Patients: UC patients (n = 20) and control subjects (n = 
22) who had a scheduled colonoscopy for disease follow­
up or for screening purposes, respectively, were enrolled 
in the study after informed consent was obtained. Only 
UC patients with no symptoms of active disease (clinical 
Mayo score 0­1); no on­going immunosuppressant, 
biologic or corticosteroid therapy; no consumption of 
probiotic formulations, antibiotics or laxatives in the last 
month; and quiescent mucosal inflammation (Mayo 
endoscopic score 0­1) at endoscopic examination were 
included in the study. Control subjects did not have 
major comorbidities and did not consume probiotic formu­
lations, antibiotics or laxatives in the month prior to their 
inclusion in the study. Normal subjects (n = 12) were 
asked to consume a commercially available formulation 
of LGG (Dicoflor 60®, AG Pharma, Rome, Italy) at the 
“regular” dose of 1.2 × 1010 CFU/d (2 packets/d) for 
seven days prior to their scheduled colonoscopies. As 
negative controls, we included normal subjects who did 
not consume LGG (n = 10). UC patients were asked 
to consume either a “regular” (1.2 × 1010 CFU/d) or 
a double (2.4 × 1010 CFU/d) dose of LGG preparation 
(Dicoflor 60®, AG Pharma, Rome, Italy) for seven days 
prior to their scheduled colonoscopies (n = 10 each 
group). All patients underwent regular bowel preparation. 
Since the standard dose of LGG was not set by specific 
studies, we arbitrarily defined the “regular” dose of LGG 
as the standard dose that is most commonly suggested 
in clinical practice, namely, 2 packets per day of Dicoflor 
60®, which is equivalent to 12 × 109 UFC/die of LGG.
At the time of colonoscopy, biopsies from the cae­
cum and rectum were collected, washed and placed in 
RNAlater solution. Total DNA was extracted, and the 
amount of mucosa­adherent LGG was quantified by RT­
PCR. Total RNA was extracted, and TNFα and IL­17 were 
quantified by RT­PCR with specific primers.
DNA/RNA extraction
For DNA and RNA extraction, QIAmp mini DNeasy and 
RNeasy miniprep kits (Qiagen, Valencia, CA, United 
States), respectively, were used according to the ma­
nufacturer’s instructions. The concentration and purity 
of extracted nucleic acids were measured with the 
GeneQuant pro RNA/DNA calculator (Amersham Phar­
macia Biotech, Uppsala, Sweden) spectrophotometer. 
Before utilization, RNA was reverse­transcribed into 
cDNA using the GeneAmp RNA PCR kit (Applied Bio­
systems, Foster City, CA, United States) according to the 
manufacturer’s instructions.
RT-PCR
PCR reactions were performed in a total volume of 20 
μL, including 16 μL SYBR Green PCR Supermix (Bio­Rad 
Pagnini C et al . Effects of LGG in the human colon
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regular dose group (4.7 ± 2.0 vs 23.3 ± 10.0, P < 0.05), 
while incubation with a higher dose of LGG (× 5) did 
not further increase the mucosal concentration (15.9 ± 
6.2, P < 0.05 vs regular dose, P = NS vs double dose) 
(Figure 4A). Similarly, incubation with a double dose of 
LGG CM significantly reduced TNFα and IL­17 expression 
compared with that of the normal dose (TNFα: 0.91 ± 
0.03 vs 0.75 ± 0.05, IL­17: 0.92 ± 0.07 vs 0.82 ± 0.05; 
P < 0.05 for both), and a higher dose of LGG CM (× 5) 
did not further reduce TNFα and IL­17 expression (TNFα: 
0.87 ± 0.05, IL­17: 0.86 ± 0.07, P = NS). The highest 
reduction was observed with the double LGG dose (25% 
and 18% reduction for TNFα and IL­17, respectively) 
(Figure 4B and C).
In vivo experiment
After 7 d of consumption of the regular dose of LGG, 
adherent bacteria were consistently detectable in bioptic 
samples, notwithstanding the bowel cleansing for the 
endoscopic procedure, and not in control biopsies from 
the colon of subjects who did not consume the probiotic 
(Figure 5A). LGG adhesion was consistent in both pro­
ximal and distal colon biopsies (7.4 ± 1.7 vs 9.0 ± 3.2) 
(Figure 5B).
Despite variability among the samples, the LGG mu­
cosal concentration was higher in UC patients who con­
sumed the double dose of LGG compared to those who 
consumed the regular dose (6.83 ± 2.97 vs 2.02 ± 1.12) 
(Figure 6A). In line with that result, UC patients who 
consumed a double LGG dose had a significant reduction 
in mucosal TNFα and IL­17 expression compared with 
that of regular dose patients (TNFα: 1.68 ± 0.22 vs 3.48 
± 0.73, 48% reduction, IL­17: 1.05 ± 0.11 vs 2.43 ± 0.57, 
43% reduction; P < 0.05 for both) (Figure 6B and C).
DISCUSSION
The present study shows for the first time that LGG 
effectively adheres to the colonic mucosa and exerts 
local anti­inflammatory effects, both in an experimental 
model and in vivo. Experimental studies have already 
highlighted the unique adhesion of LGG to the intestinal 
mucus[17]. Genetic studies have revealed that LGG has 
pili that produce a mucus­binding protein (SpaC) that 
enhances the adhesive features of the bacteria[18,19]. 
Many years ago, pivotal studies demonstrated the 
presence of cultivable LGG in bioptic samples from pa­
tients after consumption of a high dose of LGG[20,21]. In 
the present study, although a higher dose was associated 
with increased mucosal adhesion, we have demonstrated 
for the first time effective mucosal colonization by LGG 
after consumption of a standard dose, which is the mean 
dose commonly suggested for the treatment of digestive 
disorders with the LGG formulation used in the present 
work. In fact, in the studies by Alander et al[20,21], subjects 
consumed a preparation containing a dose of LGG ap­
proximately 10­20 times higher than that used in the 
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Figure 1  Lactobacillus rhamnosus GG adhesion in the normal colon and ulcerative colitis patients’ colon was evaluated by the ex vivo organ culture 
experimental model. A: Mucosal Lactobacillus rhamnosus GG (LGG) quantification from total bioptic samples showed consistent adhesion in mucosal biopsies, with 
a trend toward higher LGG concentrations in distal specimens compared with proximal specimens (n = 20 per group); B: Mucosal LGG quantification from bioptic 
samples from ulcerative colitis patients confirmed consistent bacterial adhesion after incubation (n = 15 per group). The bars represent the mean values. LGG: 
Lactobacillus rhamnosus GG; UC: Ulcerative colitis.
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Figure 2  Lactobacillus rhamnosus GG adhesion in bioptic samples 
from the rectum of ulcerative colitis patients was evaluated by the ex 
vivo organ culture experimental model. Similar concentrations of adherent 
Lactobacillus rhamnosus GG were found in the mucosa from ulcerative colitis 
patients without and with active endoscopic inflammation, as defined by Mayo 
Endoscopic Scores of ≤ 1 and 2, respectively (n = 15 per group). Mean 
± standard error is represented. LGG: Lactobacillus rhamnosus GG; UC: 
Ulcerative colitis.
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present study, and the evaluation of adherent LGG was 
performed by traditional culture technique, which has 
some limitations compared with the molecular method 
(i.e., RT­PCR) used in the current study that allows direct 
quantification of bacterial DNA content in the mucosal 
site. Despite these limitations, such studies already high­
lighted the limit of exclusive evaluation of faecal samples 
and the importance of evaluating local mucosal flora in 
bioptic samples. In fact, even though systemic effects 
could be present, the adhesion of the probiotic bacteria 
to the intestinal mucosa appears to be of paramount 
importance, at least for some of the specific, crucial 
aspects of the multiple possible mechanisms of action of 
LGG, namely, pathogen antagonism, stimulation of toll­
like receptor (TLR)­mediated pathways, restoration of 
intestinal bacterial function, and local mucosal cytokine 
modulation[22]. Accordingly, the preventive effect of a 
multiprobiotic compound on the development of inflam­
matory disease in a spontaneous model of Crohn’s 
disease (SAMP/YitFc mouse), was obtained only with 
a higher dose of probiotic that effectively induced an 
increase in the mucosal probiotic concentration in the 
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Figure 3  Effect of Lactobacillus rhamnosus GG on cytokine expression in the colon was evaluated by the ex vivo organ culture experimental model. A: 
Tumor necrosis factor alpha (TNFα) mRNA quantification in proximal (n = 15) and distal (n = 20) colon biopsies from ulcerative colitis (UC) patients incubated with 
Lactobacillus rhamnosus GG (LGG) conditioned media (CM) and control biopsies; B: IL-17 mRNA quantification in proximal and distal colon biopsies from UC patients 
incubated with LGG CM and control biopsies; C: TNFα mRNA quantification in proximal and distal colon biopsies (n = 8 per group) from normal subjects incubated 
with LGG CM and control biopsies. aP < 0.05. TNFα: Tumor necrosis factor alpha; IL: Interleukin; LGG: Lactobacillus rhamnosus GG; UC: Ulcerative colitis.
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ileal mucosa[23].
In this study, an experimental ex vivo model was 
used for the evaluation of the properties of LGG[24]. The 
utilization of models that are more representative of the 
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Figure 4  Lactobacillus rhamnosus GG dose-finding study in the ex vivo organ culture experimental model. A: Mucosal Lactobacillus rhamnosus GG (LGG) 
quantification in distal colon bioptic samples after incubation with a regular (6 × 106 CFU), double or 5-times dose of LGG. aP < 0.05 vs regular dose (n = 8 per group); 
B: TNFα mRNA quantification in distal colon bioptic samples incubated with a regular (1:10), double (2:10) or 5-times (5:10) dose of LGG conditioned media (CM) (n 
= 10 per group); C: IL-17 mRNA quantification in distal colon bioptic samples incubated with a regular (1:10), double (2:10) or 5-times (5:10) dose of LGG CM. Mean 
± standard error is represented. aP < 0.05 vs regular dose. TNFα: Tumor necrosis factor alpha; IL: Interleukin; LGG: Lactobacillus rhamnosus GG; CM: Conditioned 
media.
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Figure 5  Lactobacillus rhamnosus GG adhesion in the normal colon in vivo after 7 d of Lactobacillus rhamnosus GG administration. A: Lactobacillus 
rhamnosus GG (LGG) detection in the colon of normal subjects who did (n = 12) and did not (n = 10) consume the probiotic formulation. Relative value bars and 
visualization on an agarose gel are shown. Mean ± standard error is represented; B: Relative segmental adhesion of LGG in the proximal and distal colon biopsies (n 
= 12 per group), with the bars representing the mean values. ND: Not detectable; LGG: Lactobacillus rhamnosus GG.
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in vivo situation is becoming increasingly relevant to 
developing translational studies with consistent clinical 
application. This would ideally lead to more in­depth 
characterization of probiotic species and to the tailored 
utilization of bacteria with specific features in pathologies 
where those properties may be specifically relevant for 
therapeutic purposes. The trend towards higher LGG 
adhesion in the distal colon, observed both in vivo and 
in the ex vivo model, may offer an indirect confirmation 
of the validity of such a representative model, although 
the observed trends may be simply due to a type 
two statistical error. In a previous study, we reported 
correspondence in the data on bacterial mucosal ad­
hesion from both the experimental model and the in 
vivo setting. In fact, consistent reduction in adherent 
mucosal bacteria loads has been found in adenomatous 
polyps compared with normal mucosa and is due to 
hyperproduction of antibacterial molecules (defensins). 
Similarly, when bioptic samples were incubated with a 
probiotic formulation, mucosal adherent bacteria loads 
were significantly lower in the polyps than in the normal 
mucosa[25]. The utilization of short­term organ cultures in 
the present study represents an effective, reproducible 
and inexpensive method for the evaluation of probiotic 
adhesion and effects, and it requires materials (i.e., 
bioptic samples) that are easily available compared with 
for instance, surgical specimens. Moreover, ex vivo bioptic 
organ cultures may reflect a situation closer to the in 
vivo setting compared with other pure in vitro systems, 
such as primary cell cultures or cell lines. On the other 
hand, organ cultures may be more easily contaminated, 
and manipulations and long­term incubation are difficult 
to perform. In addition, in our method, unlike the in 
vivo setting where the epithelial cells represent the main 
interface between the luminal content and subepithelial 
compartment, the polarization of the stimulus (i.e., LGG 
CM) is not controlled, and direct paracellular stimulation 
may occur.
For genetic evaluations in the present paper, we 
used a SYBR Green­based dye detection system, which 
represents an accurate and relatively inexpensive me­
thod for DNA and RNA quantification. Since, to our know­
ledge, RT­PCR primers for SYBR Green­based systems 
that specifically target LGG have not been described, we 
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Figure 6  Lactobacillus rhamnosus GG adhesion and mucosal effect in the colon of ulcerative colitis patients. A: Mucosal Lactobacillus rhamnosus GG 
(LGG) quantification in colon biopsies of ulcerative colitis (UC) patients who consumed a regular (12 × 109 UFC/die) or a double (24 × 109 UFC/die) dose of LGG 
supplement for 7 d (n = 10 per group); B: Tumor necrosis factor alpha mRNA quantification in colon biopsies from UC patients who consumed a regular or a double 
dose of LGG supplement for 7 d. Mean ± standard error is represented; C: Interleukin-17 mRNA quantification in colon biopsies from UC patients who consumed a 
regular or a double dose of LGG supplement for 7 d. aP < 0.05. TNFα: Tumor necrosis factor alpha; IL: Interleukin; LGG: Lactobacillus rhamnosus GG; UC: Ulcerative 
colitis.
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used primers that were already developed for general 
Lactobacillus species[16]. Considering that LGG admini­
stration may affect the general composition of faecal 
microbiota[26,27], we cannot exclude the possibility that 
other Lactobacillus species might have been stimulated 
and unspecifically detected in our analysis. Nonetheless, 
the facts that we focused our analysis on the intestinal 
mucosa and not on the faeces, that the incubation time 
of the ex vivo experiments was short and that the con­
sumption time for the in vivo experiment (a week) was 
relatively short indicate that concomitant significant 
alterations in the intestinal microbiota composition is un­
likely and that the increased concentration observed with 
real­time PCR is specifically ascribable to LGG. To confirm 
our findings and to further characterize the LGG adhesion 
to the mucosa, investigations with different methods [i.e., 
fluorescence in situ hybridization (FISH)] are currently 
being performed.
Together with consistent colonization of the colonic 
mucosa, LGG demonstrated effective cytokine modu­
lation in the present study. Previous in vitro studies have 
already shown consistent anti­inflammatory properties 
of LGG. In fact, lipopolysaccharide (LPS)­activated 
macrophages derived from BALB/c mice showed reduced 
production of TNFα after incubation with LGG CM but not 
with CM from other probiotic bacteria[28]. In peripheral 
blood mononuclear cells (PBMCs) from humans, incu­
bation with LGG and other probiotic bacteria stimulated 
the modulation of cytokine production towards a re­
gulatory pattern[11]. The modulation of the cytokine 
profile is likely dependent on the induction of nuclear 
factor (NF)­κB and STAT DNA­binding activities, as de­
monstrated in human primary macrophages[29]. Moreover, 
LGG displayed anti­inflammatory effects and protection 
in several experimental models of colitis. In fact, LGG 
administration ameliorated inflammation both in DSS­
induced colitis and in human leukocyte antigen (HLA) 
B­27 transgenic rats[30,31]. Yan et al[32] demonstrated that 
a soluble protein derived from LGG, namely, p40, confers 
protection against intestinal inflammation through the 
prevention of cytokine­induced apoptosis in epithelial 
cells by means of an epithelial growth factor receptor 
(EGFR)­dependent mechanism. Recently, the same 
group demonstrated that LGG neonatal colonization in 
mice promotes intestinal development and protects from 
intestinal inflammation induced by DSS administration 
in adult mice[33], and LGG­mediated protection against 
inflammation and carcinogenesis has been demonstrated 
in the dimethyl hydrazine (DMH) model of colitis­asso­
ciated cancer[34]. More evidence about the potential 
protective role of LGG in the intestinal mucosa was 
generated in an in vitro study by Priciandaro et al[35] that 
demonstrated a reduction in apoptosis and in the loss 
of intestinal barrier function in enterocytes pretreated 
with LGG supernatant; the described study is a further 
indication of the positive effect of the metabolic products 
of LGG. The confirmation of cytokine modulation by 
LGG, which we demonstrated for the first time in the 
colonic mucosa in the present study, may be relevant 
for proposing the use of LGG in the clinical setting as a 
therapeutic option in inflammatory pathologic conditions. 
The identification of a specific molecular target of the 
probiotic bacteria was not addressed in our investigation. 
In fact, although a direct effect on mucosal cytokines 
associated with acquired immunity appears most likely, 
alternative effects, such as permeability modification, 
interaction with other commensal bacteria, or concomi­
tant action on the innate immune compartment, cannot 
be excluded. Moreover, in this proof­of­concept study, 
we intended to preliminarily demonstrate the potential 
rationale for LGG utilization in UC patients by analysing 
mucosal adhesion and the anti­inflammatory effect of the 
bacteria. We limited our investigation to the expression 
of two cytokines that are upregulated in the mucosa of 
UC patients and that are likely to play an important role 
in inflammation initiation and maintenance. Nonetheless, 
since chronic inflammation is most likely driven by multi­
ple alterations in the complex cytokine network, further 
studies are needed to better characterize the molecular 
effect of LGG, and comparison with other probiotic spe­
cies will help clarify the potential specificity of the effect 
of LGG on inflammation.
We included in the present study, for both the ex vivo 
and in vivo experiments, only UC patients with mild­
moderate disease activity. In fact, according to current 
clinical knowledge and experimental observations, the 
clinical scenario for probiotic utilization in UC patient 
management appears to be the induction of remission in 
mild­moderate flares and overall remission maintenance 
(disease prevention). Despite some encouraging clinical 
results, solid evidence for the indication and correct 
utilization of probiotics in UC patient management is 
still to come, and many questions are currently still un­
answered[36]. In this study, we demonstrated a clear 
anti­inflammatory effect in the experimental model. 
We also tested the effect on cytokines in the mucosa of 
patients consuming two different doses of LGG. In this 
“proof–of­concept” study, experimental and in vivo dose 
responses were observed after LGG administration. Since 
no analogous studies have been performed to date, in 
our experimental model, we set an LGG concentration 
of 6 × 106 CFU as the “regular dose” and an LGG CM 
concentration of 1:10 as the baseline dose for the re­
action, according to the concentrations previously used 
in the probiotic literature for in vitro studies. When 
administering a double dose of LGG or LGG CM, we 
observed an increase in mucosal adherent bacteria and 
a decrease in proinflammatory cytokine expression, 
while no further increase in adhesion or any effect on the 
cytokines was observed with a fivefold increase in LGG 
dose. A possible explanation is that doubling the dose 
of LGG in the reaction reduces the quantity of culture 
media (i.e., in a 1:10 LGG reaction culture medium is 
180 μL, while in a 1:50 LGG CM reaction it is 100 μL) 
so that bioptic samples may not have adequate culture 
conditions. Nonetheless, the identification of a real thre­
shold effect was beyond the purpose of the study and 
was not investigated. We limited our investigation to 
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the administration of two doses of oral LGG (regular 
and double) for the in vivo study, which allowed the 
preliminary confirmation of the ex vivo finding; the lack 
of safety and tolerability data for a very high dose of LGG 
supplement administration in a clinical setting also limited 
our dosing scheme. In fact, although LGG and other 
probiotic species are generally considered safe, adverse 
events are described[37], and a thorough safety evaluation 
is needed.
The novel findings of the present investigation prelimi­
narily confirm and support the feasibility and the potential 
effectiveness of the application of LGG administration 
in UC patients. Since the variability of methods and 
protocols has been a major limitation of previously pub­
lished studies on probiotic evaluation, we intended to 
restrict the patient population (i.e., mild­moderate active 
UC patients) and to standardize the methodological 
evaluation to provide the basis for a rigorous evaluation 
of LGG efficacy in this clinical scenario and eventually in 
other similar inflammatory conditions, with the ultimate 
goals of contributing to overcoming inappropriate and 
nonspecific use of probiotic bacteria and promoting more 
selective, evidence­based applications of those bacteria 
in specific clinical conditions.
ARTICLE HIGHLIGHTS
Research background
Ulcerative colitis (UC) is one of the two major forms of Inflammatory bowel 
disease (IBD), and it is characterized by a deregulated inflammation of the 
intestinal mucosa clinically presenting with symptoms of diarrhea and bloody 
stools. Despite different therapies are available, still many patients do not 
adequately respond. The therapeutic application of probiotic bacteria in this 
setting could represent an efficient and attractive option for UC patients. 
Research motivation
The research of probiotic application in IBD has been largely focused on in 
vitro systems and experimental models, and pre-clinical and clinical studies are 
characterized by an extreme dishomogeneity. Therefore, no specific indications 
for therapeutic application of probiotics (which probiotic species, doses, 
duration of therapy, and kind of UC disease severity/extension to treat) can be 
extrapolated from the literature. 
Research objectives
In order to overcome the consistent dishomogeneity of previous studies, 
the purpose of the present work was to restrict the investigation of a well 
characterized probiotic species, Lactobacillus rhamnosus GG (LGG), in a 
specific clinical setting (mild- moderate UC patients), to measurable parameters 
correlated with the potential therapeutic effect (mucosal adhesion and anti-
inflammatory effect).  
Research methods
We intended to investigate the adhesion and effect of LGG directly at the 
mucosal site by using modern genomic culture-independent techniques. An 
ex-vivo experimental model based on short-term biopsies organ culture was 
developed. Concentration and mucosal effect of LGG in colonic mucosa was 
then confirmed in vivo in UC patients and normal subjects after consumption of 
oral formulation containing LGG. 
Research results
LGG affectively adhered to the colonic mucosa, both in the experimental 
model and in vivo. Moreover, the probiotc administration reduced expression 
of two important pro-inflammatory cytokines (tumor necrosis factor alpha 
and interleukin-17). Higher mucosal concentration of the bacteria and more 
consistent reduction of pro-inflammatory cytokines has been observed 
increasing the dose of LGG.
Research conclusions
The present study demonstrated for the first time that LGG affectively adheres 
to the colonic mucosa and exerts anti-inflammatory effect, both ex vivo and in 
vivo. Moreover, we demonstrated a potential increasing of effect with higher 
dose of probiotic. Considering that probiotic utilization in clinical setting is often 
empirical and not evidence-based, the present study can put the basis for the 
evaluation of LGG in the setting of UC with specific clinical trials.  
Research perspectives
Utilization of appropriate experimental models appears crucial for the design 
of pre-clinical studies. Translational medicine studies, with both experimental 
and in vivo experiments, may contribute to correctly investigate potential 
novel treatments, and in particular to evaluate the potential application of LGG 
and other probiotic bacteria for the treatment of UC and other inflammatory 
conditions. 
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